Voxzogo 1.2 mg-EU (Vosoritide Vials) 1.2 mg

Voxzogo 1.2 mg-EU (vosoritide) is an injectable medication supplied in vials for managing certain bone growth conditions. This 10-vial pack is stored at 2–8°C and is designed for subcutaneous use. vosoritide 1.2 mg injection is prescribed for pediatric patients with specific skeletal disorders.

Strength

1.2 mg

Pack Size

10s

Storage

2-8°

Manufacturer / TM Owner

BioMarin International Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Voxzogo 1.2 mg-EU (vosoritide) is used to support healthy bone development in children with certain skeletal growth disorders. It is prescribed for conditions where bone growth is impaired, helping to improve stature outcomes. Parents often ask what vosoritide is used for when discussing treatment options for their child’s growth-related needs.

Side Effects

Voxzogo 1.2 mg-EU works by modulating the growth plate activity to promote bone elongation. Over time, it may contribute to increased height velocity in eligible pediatric patients. Common effects include injection site reactions and mild systemic responses during therapy.

Precautions & Warnings

Store Voxzogo 1.2 mg-EU vials refrigerated between 2–8°C and protect from light. Avoid freezing or shaking the vial. Always inspect the solution for particles or discoloration before use. Keep out of reach of children and pets. Dispose of used needles and vials properly according to local guidelines.

Avoid Interactions

Limited data exist on vosoritide drug interactions; however, caution is advised when combining with other medications affecting bone metabolism. No specific contraindications are reported, but healthcare providers should review all concurrent therapies. Alcohol and certain supplements may influence overall treatment response.

Frequently Asked Questions

Vosoritide 1.2 mg is used to treat certain skeletal growth disorders in pediatric patients by supporting bone elongation.

Voxzogo is administered as a subcutaneous injection, typically by a healthcare professional or caregiver trained in proper technique.

Consult a healthcare provider before combining vosoritide with other treatments, as interactions may occur.

Common effects may include injection site reactions such as redness or swelling.

Store vials refrigerated between 2–8°C and protect from light; do not freeze or shake.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.